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Abstract Efﬁcacy of a new patented proprietary combi-
nation of natural nutraceuticals (PN) containing natural
hypolipidemic as red yeast, policosanol and berberine was
tested in a large study on dyslipidemic patients in clinical
practice. A parallel, controlled, randomized, multicenter
study was designed. After 2 weeks on a stable dietary
regimen, the patients were randomized to PN 1 tablet/day
associated with diet (PN ? D) or diet alone (D) for
16 weeks. Entry criteria were: Tot-Chol [200 mg/dL or
LDL-Chol [150 mg/dL without a clear indication for
statins, or plasma triglycerides[150 mg/dL. Lipid pattern
and CV parameters were evaluated at baseline and
monthly. 1,751 patients were enrolled in 248 Italian units,
933 patients on PN ? D and 818 on D. The baseline lipid
values were: Tot-Chol 255.4 versus 243.1 mg/dL, LDL-
Chol 170.1 versus 162.2 mg/dL, HDL-Chol 50.0 versus
48.8 mg/dL, and TG 190.5 versus 184.4 mg/dL. PN
constantly and signiﬁcantly improved lipid parameters
versus D group: at 16 weeks -19.1 versus -9.4% for
Tot-Chol (p\0.001), -23.5 versus -10.8% for LDL-
Chol (p\0.001), ?11.6 versus ?4.0% for HDL-Chol
(p\0.001), -17.9 versus -11.3% for TG (p\0.001).
In conclusions, PN plus diet allows an effective
improvement of blood lipids with a signiﬁcant reduction of
global CV risk, suggesting a role for PN in CHD
prevention.
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Introduction
Lifestyle and diet changes are very important actions to be
taken to improve the cardiovascular risk and should pre-
cede any pharmacological intervention on hypercholester-
olemia, which is a well-known risk factor for coronary
artery, cerebrovascular and peripheral artery diseases
[1–3].
Dietary counseling will take advantage from the rec-
ommendations to integrate diet with the introduction of a
food supplement resulting in an improved compliance with
a dietary regimen. Indeed, previous studies suggested that
the combination of food supplements with diet leads to an
improvement of lipid metabolism control [4, 5].
Furthermore, food supplements, reinforcing the sub-
ject’s motivation to comply with the lifestyle changes, can
lead to postpone the prescription of hypo-lipidemic therapy
and the resulting risk of adverse reactions, and even to be
used as effective treatment in statin intolerant patients [6].
Many nutraceuticals are currently commercially avail-
able claiming an anti-dyslipidemic effect. The criteria for a
correct selection include the guarantees that good manu-
facturing practice is as accurate as the one adopted for drug
manufacturing, that the quality assurance allows to obtain a
ﬁnished product with a standardized constant composition,
and that clinical studies document the claims supporting
the clinical evidence of efﬁcacy and safety.
The members of Armoweb Study Group has been given in the
Appendix.
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3 3A recent opportunity offered by from the pharmaceutical
research and development is represented by a patented
proprietary combination of chemically well deﬁned natural
nutraceuticals (PN) [7]. This combination was designed to
cover more CV risk factors with active principles for the
control of plasma cholesterol (red yeast rice extract,
policosanol, berberine), of triglycerides (berberine), of
homocysteine (folic acid) and containing antioxidants
(coenzyme Q10 and asthaxantin) [4, 5, 7, 8].
The major components of PN are red yeast rice extract,
which contains monacolins that compete structurally at
HMGCoA reductase level with HMGCoA, precursor of
mevalonate, thus reducing plasma cholesterol [10, 11], and
Berberine, a natural plant extract from Berberis aristata
bark, reducing cholesterolemia by increasing LDL-Chol
receptor on the liver cell surface, and inhibiting triglycer-
ides biosynthesis via the activation of AMP activated
proteokinase [12, 13].
In clinical studies, red yeast rice signiﬁcantly reduced
total and LDL cholesterol [14] and also Berberine
improved triglycerides [15].
Clinical activity on Total and LDL cholesterol of PN
combined with diet are documented in a controlled clinical
study versus Berberine alone in moderate hypercholester-
olemia [4].
The purpose of this study was to investigate the clinical
effect on lipid proﬁle and safety of PN added to diet and
lifestyle management versus diet alone in hyperlipidemic
patients in an extended multicenter-randomized study in
clinical practice.
Materials and methods
A parallel, longitudinal, controlled, randomized, within
centers, multicenter study was carried out to compare PN
added to diet (PN ? D) versus the control group
receiving diet alone (D) by Italian general practitioners
(GPs). Each GP was supposed to enroll 10 dyslipidemic
patients (18–80 year) with or without metabolic syn-
drome, not requiring a drug therapy in accordance with
ATPIII guidelines, or who had demonstrated side effects
or had contraindications to lipid-lowering drug treatment.
Dyslipidemia was deﬁned as total cholesterol levels
[200 mg/dl and/or LDL cholesterol levels [150 mg/dl
and/or triglycerides levels [150 mg/dl. The principles of
Helsinki Declaration were applied, and speciﬁcally an
informed consent was supplied and the subject’s right to
withdraw from the study without giving reason was
clearly allowed.
Pregnant or breast-feeding women and patients treated
with anti-hypertensive and/or lipid lowering drugs were
excluded.
The composition of the patented proprietary combina-
tion of nutraceuticals investigated is as follows: red yeast
rice extract 200 mg (equivalent to 3 mg monacolins), po-
licosanol 10 mg, berberine 500 mg, 0.2 mg folic acid,
coenzyme Q10 2 mg, and asthaxantin 0.5 mg (Armolipid
Plus, Rottapharm|Madaus).
All the patients were recommended to follow a low-
glucose, low-calorie, low-fat dietary regimen in accordance
with their clinical conditions, whilst the PN group added
one tablet/day of PN. The treatment lasted 16 weeks.
Serum lipid pattern and vital signs were measured at
baseline and every 4 weeks. (Tot-Chol, HDL-Chol, LDL-
Chol, TG). Anthropometric and cardiovascular parameters
were evaluated at baseline and every 4 weeks. At the end
of the study, the patients expressed an overall judgment on
the treatment acceptance by the following score: 0 = null,
1 = moderate, 2 = fair, 3 = good, 4 = very good. Fasting
plasma glucose and lipid levels were measured by standard
methods. Waist circumference was measured at each visit
at midway between the lowest rib and the iliac crest using
an anthropometric tape. Systolic and diastolic BP values
were measured with the aid of a standard sphygmoma-
nometer after 5 min in sitting position, according to the
guidelines of the European Society of Hypertension/Euro-
pean Society of Cardiology (VB-Guidelines ESC/ESH
2007). Three BP values were obtained in the sitting posi-
tion at 2 min intervals. The averages of these measure-
ments were used for the analysis.
Adverse events, intercurrent diseases and compliance
were also checked at 4 weeks intervals during the active
treatment phase.
Statistical analysis
Sample potency for comparison between two independent
samples was run assuming a similar sample size (N1/
N2 = 1) and a small effect size (0.20) for an a-error
probability of 0.05 and a potency of 0.90, requiring a total
population sample of 1,052 observations [9]. Data were
analyzed using Excel statistical software and expressed as
average ± SEM. The statistical analysis on baseline
homogeneity and clinical efﬁcacy was carried out by
means of v
2-test and analysis of variance (ANOVA),
applied when appropriate on the patients collected from the
centers which complied with the controlled design. A
comparison between the two arms was done using absolute
differences and analyzed by ANOVA test. The null
hypothesis was rejected for 2-tail a\0.05.
A computerized internet procedure was used: each center
was endowed with individual login and password to allow a
protected access to the website http://www.armolipid.net
for data input and results analysis.
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The study was carried out in 248 centers on 1,751 dyslip-
idemic patients randomized to PN ? D (933 cases) and D
groups (818 cases).
At start no clinically signiﬁcant differences were present
between the two groups concerning age, gender, BMI and
waist circumference (Table 1).
The baseline clinical parameters, such as systolic and
diastolic blood pressure values, heart rate, Tot-Chol, LDL-
Chol, HDL-Chol, TG, fasting plasma glucose and body
weight, were clinically compared between the two study
groups (Table 2).
After 4 weeks of treatment, the average reduction of
Tot-Chol versus the baseline was -9.3% in the PN ? D
group and -5.4% in the D group and gradually reached,
respectively, -19.1 and -9.4% after 16 weeks, with
p\0.001 between treatments for all times (Fig. 1).
Likewise, the reduction of LDL-Chol was -11.9% in
PN ? D group and -5.9% in D group at the 4th week check
and progressively attained correspondingly -23.5% in
PN ? D and -10.8% in D groups at the 16th week (Fig. 2).
HDL-Chol levels showed a moderate increase from
?5.1% for PN ? D and ?1.2% for D after 4 weeks of
treatment up to ?11.6% for PN ? D and ?4.0% for D
after 16 weeks (Fig. 3).
The reduction of plasma triglycerides was -12.7% in
PN ? D group and -8.1% in D at the 4th week down to
-17.9% on PN ? D and -11.3% on D at the 16th week
(Fig. 4).
The difference between treatments was statistically
signiﬁcant at all time points for all the lipid parameters
with p\0.001.
Body weight decreased similarly in the groups, respec-
tively, for PN ? D and D groups: -2.0 and -1.9% at
4 weeks, -3.3 and -3.0% at 8 weeks, -4.5 and -4.0% at
12 weeks, -4.8 and -3.9% at 16 weeks.
A positive relationship between hypocholesterolemic
effect of PN ? D and the baseline value of LDL-Choles-
terolemia was detected at the 12th week (Fig. 5).
The normalization rate of total cholesterolemia
(B190 mg/dL) achieved during PN ? D was higher than
with diet alone and the difference was statistically signiﬁ-
cant (p\0.01) starting from the 8th week (Fig. 6).
Mainly mild and moderate unwanted events judged
by the physician with a probable, possible or certain
correlation with the treatment were reported in 27/933
cases (2.9%) during PN ? D treatment and 4/818 cases
(0.5%) during D. Treatment withdrawal was reported in
8 cases (0.86%) on PN ? D for the following reasons:
asthenia, CPK increase, diarrhea, myalgia, dyspepsia (2),
gastralgia (2). All these events, save gastralgia, had
previously appeared in the same patients also with
statins (Table 3).
The treatment efﬁcacy was assessed by the physician as
good ? very good in 71.7% of cases with PN ? D and in
24.8% of cases with D (p\0.001) and was conﬁrmed by
the treatment acceptance evaluated by the patient as
good ? very good in 80.1% of cases with PN ? D and in
29.1% of cases with D (p\0.001).
Discussion
The present randomized controlled study provides evi-
dence that the addition to diet and lifestyle changes of a
patented combination of natural nutraceuticals (PN), based
on red yeast rice extract and berberine, can improve sig-
niﬁcantly the lipid proﬁle versus diet alone in dyslipidemic
subjects in whom a hypolipidemic therapy is not yet indi-
cated or not well tolerated or is contraindicated.
The study produced reliable and robust data, because
obtained in a very large representative sample of the gen-
eral population, according to a correct methodological
design, for an adequate duration of treatment, under con-
ditions adherent to the usual daily clinical practice. These
considerations and the planned lack of diet standardization
allow the outcome of this study to be extrapolated to the
general population. Moreover, the results are in agreement
with the ones reported in a preliminary controlled double-
blind clinical study versus an active control group in
moderate hyperlipidemia [4].
The effect on lipids was independent of the diet as both
groups showed a similar and parallel reduction of body
weight during treatment, proving that the dietary restric-
tions were adopted by the whole sample.
Indeed, the opportunity of prescribing active nutraceu-
ticals can favor the compliance with the dietary changes
Table 1 Vital characteristics at study baseline (average ± SEM)
Group Age (years) Gender (% F/M) BMI (kg/m
2) Weight (kg) Waist circ. (cm)
D( n = 933) 55.6 ± 0.4 55.5/44.5 28.4 ± 0.2 78.4 ± 0.5 99.0 ± 0.5
PN ? D( n = 818) 57.3 ± 0.4 53.1/46.9 27.9 ± 0.2 77.0 ± 0.5 98.4 ± 0.5
pp \0.01 NS p\0.05 p\0.05 NS
p statistical signiﬁcance between groups
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Group SBP
(mmHg)
DBP
(mmHg)
HR
(b/min)
Tot Chol
(mg/dL)
LDL-Chol
(mg/dL)
HDL-Chol
(mg/dL)
TG
(mg/dL)
Glycaemia
(mg/dL)
D 134.3 ± 0.5 81.3 ± 0.3 74.4 ± 0.3 243.1 ± 1.0 162.2 ± 1.0 48.8± 0.4 184.4 ± 1.9 99.2 ± 20.4
PN ? D 134.3 ± 0.5 81.5 ± 0.3 73.6 ± 0.3 255.4 ± 1.1 170.1 ± 1.1 50.0 ± 0.5 190.5 ± 2.1 99.6 ± 20.8
p NS NS p\0.05 p\0.01 p\0.01 p = 0.06 p\0.05 NS
SBP systolic blood pressure, DBP diastolic blood pressure, p statistical signiﬁcance between groups
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Fig. 1 Total cholesterol reduction (%) versus baseline during
diet alone or plus PN (Average ± SEM, ***p\0.001 between
treatments)
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Fig. 2 LDL-Cholesterol reduction (%) versus baseline during
diet alone or plus PN. (Average ± SEM, ***p\0.001 between
treatments)
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Fig. 3 HDL-Cholesterol reduction (%) versus baseline during
diet alone or plus PN. (Average ± SEM, ***p\0.001 between
treatments)
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Fig. 4 Triglycerides reduction (%) versus baseline during diet alone
or plus PN. (Average ± SEM, ***p\0.001 between treatments)
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Fig. 6 Rate of normalization of total cholesterolemia (B190 mg/dL)
during diet alone or plus PN (**p\0.01 between treatments)
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followed by the patients.
Currently, the assortment of nutraceuticals is very wide
and in their selection a careful attention should be paid to
products that assure a standardized and constant composi-
tion and quality and whose claimed clinical efﬁcacy and
safety are documented.
The clinical outcome showed the efﬁcacy of the nutra-
ceuticalscontainedinPN[4,6,13,14]evenexhibitingalipid
proﬁle improvement independently of age classes, gender
and administration time during the day [16] and the
remarkable increase in HDL-Chol observed in patients with
metabolic syndrome (MetS). Moreover, PN reduced the
incidenceofMetSandimprovedtheFraminghamRiskScore
achievingasigniﬁcant change ofglobalCVriskclassversus
D[ 17]. The positive correlation between the level of LDL-
Chol at the beginning of PN treatment and the decrease of
LDL-Chol achieved after 12 weeks does not limit the use of
PN to subjects with mild hypercholesterolemia.
An important feature of PN is its good safety as shown
by the very low incidence of adverse reactions such as
constipation (0.6%), dyspepsia (0.5%), nausea (0.3%), and
diarrhoea (0.2%). The onset of myalgia, the adverse event
more worried the patients because it impairs their quality of
life, occurs in a low number of cases (0.3%), as compared
to statins, and required a precautionary withdrawal of
treatment in one patient (0.1%). In a long term study where
the patients were the controls of themselves, patients were
previously intolerant to more than one statin signiﬁcantly
improved their blood lipid picture without complaining
side effects [6]. This favorable safety proﬁle allows to
administer PN even in patients that, according to interna-
tional guidelines for higher added cardiovascular disease
risk, should be treated with statins. The occurrence of
myalgia is linked to monacolin K, whose molecular
structure correspond to a that of a mild statin. The rare
incidence of this side-effect in the PN ? D group is due to
the low daily dose of monacolin K in PN, classiﬁed as food
supplement, as compared to the correspondent statin pre-
scription drug (3 mg versus the smallest 10 mg therapeutic
dose of lovastatin). Notwithstanding the small dose of
monacolin, PN was effective as the action of monacolin K
is integrated by the whole monacolins family contained in
red yeast rice extract and by the synergistic action of ber-
berine and policosanol. In facts, berberine increases LDLR
expression by a mechanism distinct from statins and mo-
nacolin K, inhibitors of 3-hydroxy-3-methylglutaryl-
Coenzime A reductase. Experimental data provide evi-
dence that berberine and lovastatin had additive stimulating
effects on LDLR mRNA expression and that berberine
activity was not reduced at all by lovastatin [15]. These
results show the synergy of action of the combination
among berberine, red yeast rice and policosanol, previously
found in an animal study.
As ﬁnal conclusion, the variety of the available data
supports the rationale for recommending the PN combi-
nation of nutraceuticals with lifestyle changes and a bal-
anced diet as an effective approach to dyslipidemic patients
[4, 5, 17].
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